GENFIT Highlights NIS2+™ as a Potent Screening Tool in Liver Disease Clinical Trials

GENFIT, a key player in the biopharmaceutical industry with a focus on serious liver diseases, has made a significant announcement regarding its diagnostic progress. Based in Loos, France, the company has communicated its recent findings in the reputable Journal of Hepatology, emphasizing the robust performance of their NIS2+™ screening tool, which is designed for streamlining patient enrollment in clinical trials targeting Metabolic Associated Steatohepatitis (MASH). This tool represents a vital step towards enhancing the effectiveness of clinical trials by ensuring that the right candidates are selected for treatment research and development.

The NIS2+™ Diagnostic Tool

The NIS2+™ test stands as a testament to GENFIT's commitment towards advancing liver disease treatment. This non-invasive diagnostic tool is engineered to improve the selection process of patients for clinical trials by accurately identifying those with specific metabolic and liver conditions. The latest study published in the Journal of Hepatology confirms that NIS2+™ provides a reliable measure for potential participants, which is crucial for the efficient progress of MASH-related clinical trials.

Impact on GENFIT's Market Position

GENFIT, traded under the ticker GNFT, has witnessed a positive impact on its market position following this breakthrough. As a pivotal part of their research pipeline, the successful implementation of NIS2+™ has the potential to streamline their clinical trial process significantly, thereby enhancing their capability to bring effective therapies to patients quicker. The company's dedication to addressing unmet needs in rare and life-threatening liver diseases continues to drive its innovation and growth.

Global Reach and Collaboration

With its headquarters in France, GENFIT maintains a strong international presence, with operational wings in Cambridge, Massachusetts, United States, and Zurich, Switzerland. This global approach allows for a collaborative effort in tackling liver diseases, enhancing their research scope and the impact of their findings. It's this international collaboration that has enabled the successful research and validation of the NIS2+™ tool.

GENFIT, NIS2+, Hepatology